В. А. Горбунова

13.9k total citations · 4 hit papers
61 papers, 7.2k citations indexed

About

В. А. Горбунова is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, В. А. Горбунова has authored 61 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 8 papers in Surgery. Recurrent topics in В. А. Горбунова's work include Lung Cancer Treatments and Mutations (23 papers), Colorectal Cancer Treatments and Studies (20 papers) and Gastric Cancer Management and Outcomes (20 papers). В. А. Горбунова is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Colorectal Cancer Treatments and Studies (20 papers) and Gastric Cancer Management and Outcomes (20 papers). В. А. Горбунова collaborates with scholars based in Russia, United States and Germany. В. А. Горбунова's co-authors include Jaafar Bennouna, Tony Mok, Lecia V. Sequist, Wu‐Chou Su, James Chih‐Hsin Yang, Michael Boyer, Mehdi Shahidi, Dan Massey, Ki Hyeong Lee and Vera Hirsh and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

В. А. Горбунова

53 papers receiving 7.0k citations

Hit Papers

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed ... 2007 2026 2013 2019 2013 2007 2013 2010 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
    2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  2. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
  3. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
    2013 621 citations G. Bodoky, Vladimir Moiseyenko et al. profile →
  4. Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
    2010 425 citations Jaffer A. Ajani, W. Rodriguez et al. Journal of Clinical Oncology profile →

Peers

В. А. Горбунова
Oleg Lipatov Russia
Ihor Vynnychenko Ukraine
Carlo L. Bello United States
Mikhail Lichinitser Russia
Paul Bycott United States
Allen Lee Cohn United States
Petri Bono Finland
Yasushi Omuro Japan
Isan Chen United States
Christopher R. Garrett United States
Oleg Lipatov Russia
В. А. Горбунова
Citations per year, relative to В. А. Горбунова В. А. Горбунова (= 1×) peers Oleg Lipatov

Countries citing papers authored by В. А. Горбунова

Since Specialization
Citations

This map shows the geographic impact of В. А. Горбунова's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by В. А. Горбунова with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites В. А. Горбунова more than expected).

Fields of papers citing papers by В. А. Горбунова

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by В. А. Горбунова. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by В. А. Горбунова. The network helps show where В. А. Горбунова may publish in the future.

Co-authorship network of co-authors of В. А. Горбунова

This figure shows the co-authorship network connecting the top 25 collaborators of В. А. Горбунова. A scholar is included among the top collaborators of В. А. Горбунова based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with В. А. Горбунова. В. А. Горбунова is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Горбунова, В. А., et al.. (2020). Targeted therapy in the treatment of HER-2 positive breast cancer with brain metastases. Russian Journal of Oncology. 25(4). 146–153.
3.
Arkenau, Hendrik‐Tobias, Josep Tabernero, Kohei Shitara, et al.. (2018). TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Annals of Oncology. 29. viii718–viii718. 1 indexed citations
4.
5.
Ajani, Jaffer A., Mikhail Abramov, Igor Bondarenko, et al.. (2017). A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Annals of Oncology. 28(9). 2142–2148. 37 indexed citations
6.
Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2016). Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(8). 1937–1944. 65 indexed citations
7.
8.
Горбунова, В. А., et al.. (2015). DRUG THERAPY OF BREAST CANCER PATIENTS WITH METASTATIC BRAIN LESIONS.. Malignant tumours. 116–116.
9.
10.
Горбунова, В. А.. (2015). STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER. SHILAP Revista de lepidopterología. 5(1). 26–36. 1 indexed citations
11.
Mok, Tony, В. А. Горбунова, Erzsébet Juhász, et al.. (2014). A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015). Journal of Thoracic Oncology. 9(6). 848–855. 39 indexed citations
12.
Barlési, Fabrice, Arnaud Scherpereel, В. А. Горбунова, et al.. (2014). Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Annals of Oncology. 25(5). 1044–1052. 129 indexed citations
13.
Sequist, Lecia V., James Chih‐Hsin Yang, Nobuyuki Yamamoto, et al.. (2013). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology. 31(27). 3327–3334. 2461 indexed citations breakdown →
14.
Rittmeyer, Achim, В. А. Горбунова, Anders Vikström, et al.. (2013). Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089). Journal of Thoracic Oncology. 8(11). 1409–1416. 23 indexed citations
15.
Титов, К. С., et al.. (2013). Modern treatment in patients of malignant plevral effusions resistent sistem therapy. Russian Journal of Oncology. 18(3). 4–8.
16.
Ajani, Jaffer A., W. Rodriguez, G. Bodoky, et al.. (2010). Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. Journal of Clinical Oncology. 28(9). 1547–1553. 425 indexed citations breakdown →
17.
Escudier, Bernard, A Płużańska, P. Koralewski, et al.. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet. 370(9605). 2103–2111. 1722 indexed citations breakdown →
18.
Herbst, Roy S., Rafat Ansari, В. А. Горбунова, et al.. (2007). B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S335–S335. 2 indexed citations
19.
20.
Body, Jean‐Jacques, Ingo Diel, М. Р. Личиницер, et al.. (2003). Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology. 14(9). 1399–1405. 296 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oleg Lipatov Breakdown of academic impact, for papers by Ihor Vynnychenko Breakdown of academic impact, for papers by Carlo L. Bello Breakdown of academic impact, for papers by Mikhail Lichinitser Breakdown of academic impact, for papers by Paul Bycott Breakdown of academic impact, for papers by Allen Lee Cohn Breakdown of academic impact, for papers by Petri Bono Breakdown of academic impact, for papers by Yasushi Omuro Breakdown of academic impact, for papers by Isan Chen Breakdown of academic impact, for papers by Christopher R. Garrett
Rankless by CCL
2026